<DOC>
	<DOCNO>NCT02563054</DOCNO>
	<brief_summary>This study evaluate efficacy safety oral capecitabine ( Xeloda ) versus 5-fluorouracil ( 5-FU ) , combination intravenous ( IV ) cisplatin , participant advance and/or metastatic gastric cancer . The anticipated time study treatment least 6 week continue disease progression , target sample size 300 individual .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) Participants With Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Adults 18 75 year age Advanced and/or metastatic gastric cancer least 1 measurable lesion Uncontrolled infection Evidence central nervous system ( CNS ) metastases History malignancy within last 5 year , except cure basal cell cancer skin cure insitu cancer uterine cervix Radiation therapy major surgery within 4 week study drug Previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>